CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
The lung disease bronchiectasis plays out as a vicious cycle. Infection leads to inflammation followed by the impaired ability to clear the excess mucus coughed up from the lungs. These problems lead ...
Please provide your email address to receive an email when new articles are posted on . The FDA based brensocatib’s approval on phase 3 ASPEN and phase 2 WILLOW trial results. This marks the first ...
Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...
Brensocatib has demonstrated efficacy in reducing neutrophil serine protease activity and symptom burden in non-cystic fibrosis bronchiectasis. GLP-1 inhibitors show potential in managing obstructive ...
Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group. The ASPEN trial demonstrated that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results